{"id":390913,"date":"2017-09-14T00:00:00","date_gmt":"2017-09-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0032-2017-biopharma-multiple-sclerosis-treatment-algorithms-claims-data-analysis-us-2017\/"},"modified":"2026-04-15T09:57:51","modified_gmt":"2026-04-15T09:57:51","slug":"algocg0032-2017-biopharma-multiple-sclerosis-treatment-algorithms-claims-data-analysis-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0032-2017-biopharma-multiple-sclerosis-treatment-algorithms-claims-data-analysis-us-2017\/","title":{"rendered":"Multiple Sclerosis | Treatment Algorithms | Claims Data Analysis | US | 2017"},"content":{"rendered":"<p>With the availability of over a dozen disease-modifying therapies (DMTs) to treat multiple sclerosis (MS), the treatment journey for\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>\u00a0patients is varied and complex. To date, the\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>\u00a0market has accommodated a place for each therapy due to a heterogeneous disease, individualized treatment decisions, and a mix of positive and negative attributes that defines each\u00a0<abbr data-original-title=\"disease-modifying therapy\" title=\"\">DMT<\/abbr>. With every new launch, players in the\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>\u00a0space\u2014both new and old\u2014must assess where their products fit into an increasingly crowded market. Meanwhile, competing paradigms of escalation vs. early intervention with high-efficacy drugs remain a source of debate. As such, patients\u2019 journey through lines of therapy will continue to evolve. National patient-level claims data explores the current\u00a0<abbr data-original-title=\"disease-modifying therapy\" title=\"\">DMT<\/abbr>s\u2019 position in newly diagnosed and recently treated patients, examines line of therapy progression including treatment duration and switch patterns, and persistence and compliance by brand.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient share do key brands garner by line of therapy in newly diagnosed\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>patients? What are the quarterly trends in prescribing among recently treated and new diagnosed\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>\u00a0patients?<\/li>\n<li>How have newer entrants been integrated into the treatment algorithm?<\/li>\n<li>What proportion of\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>\u00a0patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with\u00a0<abbr data-original-title=\"multiple sclerosis\" title=\"\">MS<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em>\u00a0provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390913","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390913\/revisions"}],"predecessor-version":[{"id":394037,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390913\/revisions\/394037"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}